The portfolio maintains a sizable cost advantage over competitors, priced within the lowest fee quintile among peers.
iShares Biotechnology ETF IBB
Morningstar’s Analysis IBB
Will IBB outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 49.5
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Gilead Sciences Inc | 8.76 | 661.4 Mil | Healthcare |
Amgen Inc | 7.82 | 590.6 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 7.61 | 574.6 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 7.17 | 541.4 Mil | Healthcare |
IQVIA Holdings Inc | 4.06 | 306.9 Mil | Healthcare |
Alnylam Pharmaceuticals Inc | 3.35 | 253.0 Mil | Healthcare |
Mettler-Toledo International Inc | 3.06 | 230.7 Mil | Healthcare |
argenx SE ADR | 2.71 | 204.6 Mil | Healthcare |
Biogen Inc | 2.65 | 199.8 Mil | Healthcare |
BioNTech SE ADR | 2.34 | 176.5 Mil | Healthcare |